AN2 Therapeutics, Inc. (ANTX) has released an update.
AN2 Therapeutics, Inc. has put a hold on enrolling new patients in its Phase 3 clinical trial for epetraborole, a treatment for MAC lung disease, due to preliminary findings suggesting the drug may be less effective than anticipated. This pause, not related to safety concerns, allows for a thorough review of the existing data and expert recommendations for potential protocol modifications. Despite this, the trial has already seen a high enrollment rate, with the company planning to release key Phase 2 results by summer 2024. Patients currently in the trial will continue their treatment as the company assesses the best path forward.
For further insights into ANTX stock, check out TipRanks’ Stock Analysis page.
